GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy

Publication date: Available online 7 May 2018

Source: Seminars in Oncology

Author(s): Mayrel Labrada, Denise Dorvignit, Giselle Hevia, Nely Rodríguez-Zhurbenko, Ana M. Hernández, Ana M. Vázquez, Luis E. Fernández

Abstract

Numerous molecules have been considered as targets for cancer immunotherapy because of their levels of expression on tumor cells, their putative importance for tumor biology, and relative immunogenicity. In this review we focus on the ganglioside GM3(Neu5Gc), a glycosphingolipid present on the outer side of the plasma membrane of vertebrate cells. The reasons for selecting GM3(Neu5Gc) as a tumor-specific antigen and its use as a target for cancer immunotherapy are discussed, together with the development of antitumor therapies focused on this target by the Center of Molecular Immunology (CIM, Cuba).

https://ift.tt/2KImuoL